MARKET WIREYahoo! Finance Canada • 18h ago
MannKind Corporation (MNKD) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.
Why MNKD Stock Traded Steady Today — RQD Quant Desk Flash
$3.50 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $3.49
MannKind Corporation (MNKD) carries a Roarable Rating of D+ (Sell) with 56/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $1.13B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on MNKD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is MNKD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, MannKind Corporation (NASDAQ: MNKD) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $3.50 (0.00% 1D, market cap $1.13B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, MNKD ranks #200 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does MNKD compare to AVLN and AMPH in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MNKD carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of 92.3%, and ROIC of 54.5%. By comparison, AVLN (Avalyn Pharma Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC —, cap $1.14B) and AMPH (Amphastar Pharmaceuticals Inc.) posts a B grade (72/100 RQD, P/E 11.7x, ROIC 9.0%, cap $1.18B). Among the 5-stock peer group, AMPH leads on earnings multiple (11.7x) while MNKD leads on capital efficiency (54.5% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for MNKD?
▼
Per MNKD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000899460), MannKind Corporation generated $349.0M in revenue (+22.2% YoY), $5.9M in net income, and $13.7M in free cash flow against $792.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $3.49 (-0.19%)🧬 Disciplined Float (-0.32% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 3.9% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 56/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.4% avg 90D alpha vs SPY • 51.8% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw C- · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-0.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MNKD)Realized 20D OHLCV Swing Band: ±10.4%
Deterministic 5-Pillar Attribution (56/100 Composite)
🔍 WHY MNKD SCORES 56/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+14/20 pts (25% of score)
SEC XBRL FY 2025 (10-K): 3.9% FCF Margin ($13.7M FCF) & 92.3% Gross Margin
▲ #2 Bullish Driver: Insider Conviction & Share Dilution+13/20 pts (23% of score)
SEC Form 4 / 13F Thermometer: 65% Net Buy • Disciplined Float (-0.32% YoY Shares)
▼ #1 Drag / Risk Factor: Macro Regime Fit8/20 pts (-12 pt drag)
Macro rate sensitivity & RSI-14 (55.6) create a -12 pt regime headwind
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$3.05+1.6% Next Q
48
Q2 (-2Q)Grade C-$3.10+6.1% Next Q
51
Q3 (-1Q)Grade C-$3.29+6.4% Next Q
53
CurrentGrade D+$3.50-0.4% Hist 90D α
56
Trajectory: D (48) → D+ (56)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the MNKD Bull Thesis Could Fail
Even with a 56/100 (D+) score, MNKD faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
⚠️ Forensic Kill-Switch #2
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($3.56) or 200D SMA ($3.71) invalidates the momentum regime and cuts Target Base ($3.47) toward Bear Floor ($2.71).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $MNKD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MNKD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why MNKD Stock Traded Steady Today — RQD Quant Desk Flash
MannKind Corporation (MNKD) slipped 0.00% to $3.50, trading at 30% of its 52-week range ($2.23 – $6.51). Stretched risk/reward at current multiples (55% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 30% of its 52-week range ($2.23 – $6.51) with RSI-14 at 55.6 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±10.4% around $3.50 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 92.3% gross margin and $13.7M annual free cash flow.
Live MNKD Headlines & Catalysts
MARKET WIREYahoo! Finance Canada • 21h ago
MannKind Corporation (MNKD) Interactive Stock Chart - Yahoo FinanceYahoo! Finance Canada report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
A heart-failure injector delivers a full dose in under 10 seconds. Urine output was similar to treatment into a vein.Stock Titan report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Manila Times • 1d ago
MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026The Manila Times report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Does MannKind (MNKD) Have a Differentiated Cardiorenal Strategy or Just Incremental Delivery Innovation?Yahoo Finance report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREad-hoc-news.de • 1d ago
MannKind stock sets November 5 date for third-quarter resultsad-hoc-news.de report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.
RISK WATCHhttps://www.dars.gov.et/ • 1d ago
MNKD Q2 2026 Earnings: Wider-Than-Expected Loss Drives Modest Share Decline - Downward Estimate Revisionhttps://www.dars.gov.et/ report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
MannKind to Participate in the Chardan Healthcare ConferenceYahoo Finance report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 2d ago
Can MannKind (MNKD) Still Be A Bargain On Cash Flow?MannKind has had a rough stretch in 2026, with the share price down 37.5% year to date, which puts fresh focus on whether the current US$3.50 level lines up with what its cash flows can support. With revenue now more hea
MARKET WIREYahoo • 13d ago
MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX GrowthMannKind (NASDAQ:MNKD) Chief Executive Officer Mike Castagna said the company is advancing an inhaled version of nintedanib into a global Phase 2 study for idiopathic pulmonary fibrosis, or IPF, following early safety an
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MNKD)
- ✓Walkthrough of MNKD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
MNKD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +24.56%▼ DESCENDING CHANNEL
2026-11-03O $3.50H $3.50L $3.50C $3.50VOL 2.01M
RES: $4.20SUP: $2.70SMA50: $3.56SMA200: $3.71
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
MNKD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
23.7%/yr Implied 5Y Growth
vs. +22.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on MNKD today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for MNKD. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MNKD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MNKD)
Health Care Rank #200 of 1016
⚔️ AVLN vs MNKD Full Matrix →
1. Head-to-Head Health Care Peer Comparison (MNKD vs. AVLN, AMPH, VSTM, JANX)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, MannKind Corporation (MNKD) ranks #200 by composite RQD confidence (56/100, grade D+) and #342 by equity capitalization ($1.13B). Within this direct 5-issuer industry benchmark cohort, AMPH leads on earnings valuation at 11.7x trailing P/E, while MNKD leads on capital efficiency and profitability with 54.5% ROIC and 92.3% gross margin. AMPH currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with MNKD at 56/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MNKD
ACTIVE
MannKind Corporation | D+ | 56/100 | — | 92.3% | 54.5% | 0.00% | $1.13B | Benchmark Subject |
| AVLN Avalyn Pharma Inc. | D | 44/100 | — | — | — | -0.31% | $1.14B | /avln-vs-mnkd → |
| AMPH Amphastar Pharmaceuticals Inc. | B | 72/100 | 11.7x | 49.5% | 9.0% | +2.93% | $1.18B | /amph-vs-mnkd → |
| VSTM Verastem Inc. | D- | 36/100 | — | — | -35.0% | +0.93% | $1.18B | /vstm-vs-mnkd → |
| JANX Janux Therapeutics Inc. | D- | 37/100 | — | — | -13.8% | -2.02% | $1.07B | /janx-vs-mnkd → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000899460In its most recent audited fiscal period (FY2025, filed 2025-12-31), MannKind Corporation (MNKD) reported GAAP revenue of $349.0M (+22.2% vs. FY2024 revenue of $285.5M , and +75.4% cumulative change since FY2023) , GAAP net income of $5.9M, operating cash flow of $18.3M, and free cash flow of $13.7M (-58.3% YoY). On the balance sheet, MNKD closed FY2025 with $792.2M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $349.0M | $5.9M | $18.3M | $13.7M | $792.2M | — |
| FY2024 (FY) | 2024-12-31 | $285.5M | $27.6M | $42.5M | $32.8M | $393.8M | — |
| FY2023 (FY) | 2023-12-31 | $199.0M | -$11.9M | $34.1M | $34.1M | — | — |
3. MNKD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs MNKD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, MannKind Corporation (NASDAQ: MNKD) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $3.50 (0.00% 1D, market cap $1.13B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, MNKD ranks #200 in composite RQD confidence.
How does MNKD compare to AVLN and AMPH in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MNKD carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of 92.3%, and ROIC of 54.5%. By comparison, AVLN (Avalyn Pharma Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC —, cap $1.14B) and AMPH (Amphastar Pharmaceuticals Inc.) posts a B grade (72/100 RQD, P/E 11.7x, ROIC 9.0%, cap $1.18B). Among the 5-stock peer group, AMPH leads on earnings multiple (11.7x) while MNKD leads on capital efficiency (54.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for MNKD?
Per MNKD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000899460), MannKind Corporation generated $349.0M in revenue (+22.2% YoY), $5.9M in net income, and $13.7M in free cash flow against $792.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is MNKD trading relative to its 50-day, 200-day, and 52-week technical levels?
MNKD last traded at $3.50 (0.00% on volume of 2,009,459 shares), positioning the stock -1.69% below its 50-day simple moving average ($3.56) and -5.66% below its 200-day simple moving average ($3.71). Across its 52-week range of $2.23 to $6.51, MNKD sits at the 29.7% percentile with a 14-day RSI of 55.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±10.4% ($3.14 to $3.86).
MNKD Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is MNKD stock moving today?
Why MNKD Stock Traded Steady Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (55% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 56/100 (D+)
✓ STAGE-C NUMBER FIREWALL VERIFIED
MNKD — MannKind Corporation: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:30:37Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, MNKD scores 55 out of 100 (letter grade D+), with the verdict "Roarable Sell — Weak Fundamentals / Trim." The five pillars are:
- Fundamental Cash Engine (14/20): Per the Roarable RQD rating, this pillar reflects ROIC of 54.5% and an FCF yield of 1.22%. The high ROIC contrasts with a thin 1.22% FCF yield, meaning the return on invested capital is not translating into proportionate cash returns to a buyer at the current price.
- Whale / 13F Flow (8/20): Per the Roarable RQD rating, institutional accumulation and options positioning score weakly. The supporting holder data is not available in source data, so the score cannot be traced to specific filings in this dossier.
- Insider Conviction (13/20): Per the Roarable RQD rating, SEC Form 4 and Congressional PTR cluster flow score moderately. Individual transactions are not itemized in the source data.
- Macro Regime Fit (8/20): Per the Roarable RQD rating, beta of 1.0 and sector sensitivity score weakly, indicating limited defensive character relative to the market.
- Forensic Balance Sheet (12/20): Per the Roarable RQD rating, Altman Z of 0.2 is a distress-zone reading, Piotroski F of 7/9 is a relatively healthy signal, and Debt/Equity of 0.5 is moderate. The conflict between a distressed Altman reading and a strong Piotroski reading is a key tension for an investor to weigh.
For a prospective investor evaluating the stock today, the rating implies that upside depends on the cash engine converting into free cash flow and on the balance sheet stabilizing, while the weak macro-fit and flow scores suggest limited institutional tailwind. The 55 score and "Trim" verdict frame the stock as one where risk currently outweighs the visible fundamental support.
Business
MannKind Corporation (MNKD) is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company has a market capitalization of $1.1B. The source data does not describe specific products, customers, or revenue streams, so the business model cannot be detailed beyond its sector and industry classification. Per the SEC financials, reported revenue for FY 2025 was $349.0M.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $349.0M | $38.8M | $5.9M | N/A | $13.7M | $74.9M | N/A |
| FY 2024 | $285.5M | $72.6M | $27.6M | N/A | $32.8M | $46.3M | N/A |
| FY 2023 | $199.0M | $8.7M | $-11.9M | N/A | $34.1M | N/A | N/A |
Per the market data, gross margin is 92.3%, operating margin 11.1%, and net margin 1.7%, with ROIC at 54.5%. Per the Roarable RQD rating, the Altman Z-Score is 0.2 and the Piotroski F-Score is 7/9, with Debt/Equity at 0.5. Revenue grew from $199.0M in FY 2023 to $349.0M in FY 2025, while net income fell from $27.6M in FY 2024 to $5.9M in FY 2025. Cash rose from $46.3M to $74.9M over the same span.
Recent Catalysts & News Wire Analysis
Per the recent news feed, six items were logged, all tagged to MNKD with a YELLOW light and MARKET WIRE impact label. Two items are generic market-profile pieces, one references a heart-failure injector delivering a full dose in under 10 seconds with urine output similar to intravenous treatment, one covers a cardiorenal strategy question, and two announce that MannKind will report third-quarter financial results and host a conference call on November 5, 2026. The third-quarter report date is the nearest scheduled catalyst in the source data. Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are recorded.
Open Questions
- What are the reported EPS and trailing P/E figures, given that the financials table lists EPS as N/A and P/E as unavailable?
- What is the company's debt balance, given that debt is N/A across all reported periods despite a stated Debt/Equity of 0.5?
- Why did net income decline from $27.6M in FY 2024 to $5.9M in FY 2025 while revenue and operating income moved in differing directions?
- What products and revenue sources drive the reported $349.0M in FY 2025 revenue?
- What would the November 5, 2026 third-quarter results need to show to shift the Altman Z-Score or FCF yield meaningfully?
MNKD Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for MannKind Corporation (MNKD) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo! Finance Canada • 18h ago
MannKind Corporation (MNKD) Stock Price, News, Quote & History Yahoo! Finance Canada report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 21h ago
MannKind Corporation (MNKD) Interactive Stock Chart - Yahoo Finance Yahoo! Finance Canada report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
A heart-failure injector delivers a full dose in under 10 seconds. Urine output was similar to treatment into a vein. Stock Titan report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Manila Times • 1d ago
MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026 The Manila Times report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Does MannKind (MNKD) Have a Differentiated Cardiorenal Strategy or Just Incremental Delivery Innovation? Yahoo Finance report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ad-hoc-news.de • 1d ago
MannKind stock sets November 5 date for third-quarter results ad-hoc-news.de report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago
MNKD Q2 2026 Earnings: Wider-Than-Expected Loss Drives Modest Share Decline - Downward Estimate Revision https://www.dars.gov.et/ report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
MannKind to Participate in the Chardan Healthcare Conference Yahoo Finance report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
MNKD Bull vs. Bear Conversation Board — What's Your Call at $3.50?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MNKD 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $3.78 (+8.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is MNKD (D+ • RQD 55/100) a Buy at $3.50?
Welcome to the MNKD (MannKind Corporation) Roar Pit. Current RQD Composite is 55/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Pharmaceutical Preparations. Bulls point to capital efficiency (54.5% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $2.87 (-18.0%)
Spot @ $3.50 Pump the brakes on MNKD — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on MNKD, but look at what you are paying: current EV/EBITDA multiples with 92.3% gross margins. Unless MannKind Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
MI MidwestValue Verified K Arena Trader 🐂 BULLISH
🎯 Target: $4.41 (+26.0%)
Spot @ $3.50 MNKD cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on MNKD, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $3.50 (52-wk range $2.23 - $6.51), any beat on forward guidance forces shorts and underweight funds to chase.